Renal Allograft Tolerance Through Mixed Chimerism

Trial Profile

Renal Allograft Tolerance Through Mixed Chimerism

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 24 Apr 2017

At a glance

  • Drugs Rituximab (Primary) ; Siplizumab (Primary)
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Dec 2013 Planned end date changed from 1 Aug 2016 to 1 Oct 2018 as reported by
    • 01 Mar 2013 Status changed from not yet recruiting to recruiting as reported by
    • 08 Feb 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top